贝伐珠单抗靶向治疗联合FOLFOX6化疗方案治疗晚期结直肠癌的效果及对患者免疫功能的影响

Effect of bevacizumab targeted therapy combined with FOLFOX6 chemotherapy on patients with colorectal cancer and its influence on immune function

目的探讨贝伐珠单抗靶向治疗联合FOLFOX6化疗方案(奥沙利铂+亚叶酸钙+5-氟尿嘧啶)治疗晚期结直肠癌的效果及对患者免疫功能的影响。方法抽取2013年5月至2018年5月苏州大学附属常熟医院收治的84例晚期结直肠癌患者,按照随机数字表法分为观察组与对照组,每组42例。对照组采用FOLFOX6化疗方案治疗,在此基础上,观察组加用贝伐珠单抗靶向治疗。治疗4个周期后,比较两组临床疗效、近期生存率、免疫功能。结果治疗4个周期后,观察组总有效率高于对照组(P<0.05);治疗4个周期后,两组免疫球蛋白G(IgG)、免疫球蛋白A(IgA)水平均低于治疗前(P<0.05),但两组比较差异未见统计学意义(P>0.05);观察组1年与2年生存率均略高于对照组,但组间比较差异未见统计学意义(P>0.05)。结论晚期结直肠癌患者采用贝伐珠单抗靶向治疗联合FOLFOX6化疗方案治疗可有效提高临床疗效,并且不会加剧免疫功能损伤。

Objective To investigate the effect of bevacizumab targeted therapy combined with FOLFOX6 chemotherapy(oxaliplatin+calcium folinate+5-fluorouracil)on patients with colorectal cancer and its influence on immune function.Methods Eighty-four patients with colorectal cancer in Changshu First People’s Hospital from May 2013 to May 2018 were randomly divided into observation group and control group,with 42 cases in each group.The control group was treated with FOLFOX6 chemotherapy,and the observation group was treated with bevacizumab.After 4 cycles of treatment,the clinical efficacy,short-term survival rate and immune function of the two groups were compared.Results After 4 cycles of treatment,the total effective rate of the observation group was higher than that of the control group(P<0.05);after 4 cycles of treatment,the levels of immunoglobulin G(IgG)and immunoglobulin A(IGA)in the two groups were lower than those before treatment(P<0.05),but there was no significant difference between the two groups(P>0.05);the 1-year and 2-year survival rates of the observation group were slightly higher than those of the control group,but there was no significant difference between the two groups(P>0.05).Conclusions Bevacizumab targeted therapy combined with FOLFOX6 chemotherapy can effectively improve the clinical efficacy of colorectal cancer patients,and it will not aggravate the immune function damage.